[
  {
    "ts": null,
    "headline": "NFJ: Cheap Relative To Peers, But Now Is Not The Best Time To Buy",
    "summary": "NFJ: Cheap Relative To Peers, But Now Is Not The Best Time To Buy",
    "url": "https://finnhub.io/api/news?id=168deb867234092d90e5e97e7d4642b73edb0b4085aecf2ef07aecb88440ff38",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753812407,
      "headline": "NFJ: Cheap Relative To Peers, But Now Is Not The Best Time To Buy",
      "id": 136125980,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=168deb867234092d90e5e97e7d4642b73edb0b4085aecf2ef07aecb88440ff38"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income",
    "summary": "Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.",
    "url": "https://finnhub.io/api/news?id=f7badad3ab13cf1b10a68209421d320f259925f861568da1837aad25ae5649a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753806453,
      "headline": "Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income",
      "id": 136129996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options.",
      "url": "https://finnhub.io/api/news?id=f7badad3ab13cf1b10a68209421d320f259925f861568da1837aad25ae5649a8"
    }
  },
  {
    "ts": null,
    "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
    "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
    "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753802160,
      "headline": "Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.",
      "id": 136119118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.",
      "url": "https://finnhub.io/api/news?id=2882e025de234379523055e798c0734413f211014488659f7fbc8603b3ac1eda"
    }
  },
  {
    "ts": null,
    "headline": "Chondrosarcoma Market Report 2025-2035: Increased Research on Rare Skeletal Tumors and IDH1/2 Mutation-targeted Therapies",
    "summary": "The Global Chondrosarcoma Market is witnessing significant advancements, particularly in diagnostics and treatment options for this rare cartilage-forming cancer. Innovations in radiographic imaging, next-generation sequencing, and minimally invasive surgeries have improved diagnostic accuracy. The introduction of targeted therapies like DR5 agonists (INBRX-109), IDH1 inhibitors (ivosidenib), and EZH2 inhibitors is transforming outcomes for unresectable cases. Despite challenges such as chemothe",
    "url": "https://finnhub.io/api/news?id=3f3be956ea79523d4a7b85c177b0b8f4fabc38624a895fec2da7f972bd42eda9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753800780,
      "headline": "Chondrosarcoma Market Report 2025-2035: Increased Research on Rare Skeletal Tumors and IDH1/2 Mutation-targeted Therapies",
      "id": 136119355,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Chondrosarcoma Market is witnessing significant advancements, particularly in diagnostics and treatment options for this rare cartilage-forming cancer. Innovations in radiographic imaging, next-generation sequencing, and minimally invasive surgeries have improved diagnostic accuracy. The introduction of targeted therapies like DR5 agonists (INBRX-109), IDH1 inhibitors (ivosidenib), and EZH2 inhibitors is transforming outcomes for unresectable cases. Despite challenges such as chemothe",
      "url": "https://finnhub.io/api/news?id=3f3be956ea79523d4a7b85c177b0b8f4fabc38624a895fec2da7f972bd42eda9"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?",
    "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=a400422a5bfc781db71af7ceb98e681df9fe28ef887027c7bccbaf4fd8623062",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753797627,
      "headline": "Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?",
      "id": 136119190,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=a400422a5bfc781db71af7ceb98e681df9fe28ef887027c7bccbaf4fd8623062"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Stock: Analyst Estimates & Ratings",
    "summary": "Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.",
    "url": "https://finnhub.io/api/news?id=e1b264f41bc39a1f8ed46e6a700e66b075b81131951f951a608ae9055f7f52b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753797493,
      "headline": "Pfizer Stock: Analyst Estimates & Ratings",
      "id": 136119357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the stock’s future performance.",
      "url": "https://finnhub.io/api/news?id=e1b264f41bc39a1f8ed46e6a700e66b075b81131951f951a608ae9055f7f52b9"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?",
    "summary": "MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.",
    "url": "https://finnhub.io/api/news?id=b907ff4df86d247236f04e8fce52bfa216457f8eb54af620ba725c09494accbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753791960,
      "headline": "Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?",
      "id": 136119271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.",
      "url": "https://finnhub.io/api/news?id=b907ff4df86d247236f04e8fce52bfa216457f8eb54af620ba725c09494accbd"
    }
  },
  {
    "ts": null,
    "headline": "BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten",
    "summary": "TORONTO, July 29, 2025--BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.",
    "url": "https://finnhub.io/api/news?id=5ec9df651fe2502d125a298ef2d58c548d64d82cc742143f1d2ce741853ccce6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753790400,
      "headline": "BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten",
      "id": 136117116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "TORONTO, July 29, 2025--BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors.",
      "url": "https://finnhub.io/api/news?id=5ec9df651fe2502d125a298ef2d58c548d64d82cc742143f1d2ce741853ccce6"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Tops Q2 Earnings Estimates",
    "summary": "Merck (MRK) delivered earnings and revenue surprises of +5.97% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=4c5ab90c0ae1ef4783d9d88bf3ba75beca9ee6250e11d8052fa941dab1dd7878",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753789202,
      "headline": "Merck (MRK) Tops Q2 Earnings Estimates",
      "id": 136119273,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered earnings and revenue surprises of +5.97% and -0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=4c5ab90c0ae1ef4783d9d88bf3ba75beca9ee6250e11d8052fa941dab1dd7878"
    }
  },
  {
    "ts": null,
    "headline": "North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace",
    "summary": "The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI an",
    "url": "https://finnhub.io/api/news?id=ed8514fa24e8f3c6c9589145aa8d07c4c0f7ef3f78304c0216d80845aaf8ecf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753776360,
      "headline": "North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace",
      "id": 136117117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The North America Clinical Trials Market is projected to grow from US$ 20.07 billion in 2024 to US$ 33.91 billion by 2033, registering a CAGR of 6.00% from 2025 to 2033. Key drivers include the increasing demand for novel treatments, rising prevalence of chronic conditions like COVID-19, diabetes, and various cancers, as well as supportive government R&D investments. The U.S. leads with robust infrastructure, top-notch research facilities, and significant technological advancements such as AI an",
      "url": "https://finnhub.io/api/news?id=ed8514fa24e8f3c6c9589145aa8d07c4c0f7ef3f78304c0216d80845aaf8ecf6"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they should continue to hold the stock or sell it. In response, Cramer stated: “I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s […]",
    "url": "https://finnhub.io/api/news?id=bba0c8322169d354065d68dff88d56b2f61b58222625a9e7285dbd98e802c730",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753766916,
      "headline": "Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does”",
      "id": 136113388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they should continue to hold the stock or sell it. In response, Cramer stated: “I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s […]",
      "url": "https://finnhub.io/api/news?id=bba0c8322169d354065d68dff88d56b2f61b58222625a9e7285dbd98e802c730"
    }
  }
]